Research groups that include NCMM Group Leader, Irep Gözen, and Director Kjetil Taskén, will receive funding as part of UiO: Life Science’s Convergence Environment programme
March edition of the NCMM Newsletter
NCMM is delighted to congratulate Senior Engineer on receiving the UiO Prize for outstanding work for Health Environment and Safety (HSE) in the workplace.
Findings from a Centre for Digital Life Norway report into the digitalisation of Norway’s bio economy is unveiled at the Digital Life Conference 2017.
Two leading scientists from two Nordic EMBL Partnership sites, DANDRITE (Danish Research Institute of Translational Neuroscience) and MIMS (The Laboratory for Molecular Infection Medicine Sweden), have both been awarded prestigious prizes.
Professor Per Ottar Seglen, a guest researcher at NCMM, has been awarded the prestigious King Olav V’s Prize for Cancer Research 2017.
NCMM is very pleased to announce that Professor Olli Kallioniemi has been appointed as the new NCMM Scientific Advisory Board (SAB) member. He will succeed Leif Groop.
February edition of the NCMM Newsletter.
Congratulations to NCMM Group Leader, Anthony Mathelier, who has been successful with an application for event support from UiO:Life Science.
NCMM’s Director, Professor Kjetil Taskén, addressed guests at day two of the Oslo Life Science Conference, talking about the future in personalized cancer therapy.
A closer look at NCMM's recent annual Network Meeting at Oslo Science Park
NCMM’s Director, Professor Kjetil Taskén, has been interview by the University of Oslo’s flagship science and technology news outlet, Titan.uio.no, ahead of his appearance at the Oslo Life Science Conference on the 16 February.
Get the latest news and updates from NCMM in a new monthly newsletter.
Nikolina Sekulic has received a prestigious Young Talent award from the Research Council of Norway for her work in chromatin biology.
NCMM and EATRIS Norway have been awarded a grant from the Helse-EU programme at the Research Council of Norway to recruit an EATRIS (European Infrastructure for Translational Medicine) Coordinator.
The merger between Centre for Molecular Medicine Norway (NCMM) and the Biotechnology Centre of Oslo (BiO) formally came into effect on 2 January 2017.
We congratulate NCMM Director Kjetil Taskén on receiving King Olav V Price for Cancer Research 2016 during a ceremony at the University of Oslo on June 6.
Bains' discovery that patients diagnosed with colorectal cancer while on aspirin have better survival rate than others, is published in Journal of Clinical Oncology.
We congratulate NCMM and BiO Director Kjetil Taskén on receiving King Olav V Price for Cancer Research 2016.
The NCMM Board appoints 5 new Associate Investigators and 7 new Young Associate Investigators.
EI3POD was lauched in July 2015 and opens its doors to academia and industry to foster cross-institutional academic research, industry collaborations and the development of commercial know-how and entrepreneurship.
EI3POD is co-funded by EMBL and the European Commission’s Horizon 2020 Marie Skłodowska-Curie Actions.
The Norwegian Research Council today published the results of its latest call for new research infrastructures under the National Infrastructure programme. In total 1.3 billion NOK is allocated to new infrastructure investments. One of the applications invited for contract negotiations is NOR-OPENSCREEN, a distributed infrastructure for chemical biology and marine bioprospecting with the Universities of Oslo, Tromsø, Bergen and SINTEF (Trondheim) as partners.
NCMM is seeking outstanding candidates for new Associate Investigators in an open call with deadline September 1.
NCMM as a national center offers a mechanism for Young Associate Investigators and presently has an open call with application deadline September 1.
The 2015 American Society of Clinical Oncology (ASCO) Meeting took place in Chicago on May 29 - June 2. This Annual Meeting brings together 30,000 oncology professionals from around the world. On May 30 NCMM PhD fellow Simer Bains gave an oral presentation entitled "Impact of aspirin as secondary prevention in an unselected cohort of 25 644 patients with colorectal cancer: A population-based study".